Last reviewed · How we verify
Folfox with avastin
Folfox with avastin is a Chemotherapy combination + monoclonal antibody (anti-VEGF) Small molecule drug developed by Sherief Abd-Elsalam. It is currently in Phase 3 development for Metastatic colorectal cancer, Advanced non-small cell lung cancer (in some regimens). Also known as: folfox 4.
FOLFOX chemotherapy combined with bevacizumab (Avastin) kills cancer cells through DNA damage while blocking tumor blood vessel formation.
Folfox with Avastin is a treatment regimen used for various types of cancer, including metastatic colorectal cancer, stage II/III colon cancer, and unresectable colorectal cancer. It involves the combination of folinic acid, fluorouracil, and oxaliplatin with bevacizumab (Avastin), a small molecule that targets vascular endothelial growth factor (VEGF).
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Oncology Phase 3 boost
+3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Folfox with avastin |
|---|---|
| Also known as | folfox 4 |
| Sponsor | Sherief Abd-Elsalam |
| Drug class | Chemotherapy combination + monoclonal antibody (anti-VEGF) |
| Target | DNA (chemotherapy); VEGF (bevacizumab) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOX is a combination chemotherapy regimen (5-fluorouracil, leucovorin, and oxaliplatin) that damages cancer cell DNA and inhibits thymidylate synthase to prevent replication. Bevacizumab is a monoclonal antibody targeting VEGF that inhibits angiogenesis, starving tumors of blood supply. Together, they provide dual mechanisms: direct cytotoxic chemotherapy plus anti-angiogenic therapy.
Approved indications
- Metastatic colorectal cancer
- Advanced non-small cell lung cancer (in some regimens)
Common side effects
- Neutropenia
- Neuropathy (peripheral)
- Diarrhea
- Nausea/vomiting
- Anemia
- Hypertension
- Proteinuria
- Bleeding/thrombosis
Key clinical trials
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer (PHASE2)
- Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors (PHASE1)
- Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial (PHASE3)
- A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Folfox with avastin CI brief — competitive landscape report
- Folfox with avastin updates RSS · CI watch RSS
- Sherief Abd-Elsalam portfolio CI
Frequently asked questions about Folfox with avastin
What is Folfox with avastin?
How does Folfox with avastin work?
What is Folfox with avastin used for?
Who makes Folfox with avastin?
Is Folfox with avastin also known as anything else?
What drug class is Folfox with avastin in?
What development phase is Folfox with avastin in?
What are the side effects of Folfox with avastin?
What does Folfox with avastin target?
Related
- Drug class: All Chemotherapy combination + monoclonal antibody (anti-VEGF) drugs
- Target: All drugs targeting DNA (chemotherapy); VEGF (bevacizumab)
- Manufacturer: Sherief Abd-Elsalam — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Metastatic colorectal cancer
- Indication: Drugs for Advanced non-small cell lung cancer (in some regimens)
- Also known as: folfox 4
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing